[
Abstract]
[
Full Text HTML]
[
Full Text PDF] （in Japanese / 894KB）
[PDF: Members Only] J.Jpn. Surg. Soc.. 124(5): 416-421, 2023
Feature topic
INNOVATIONS IN CHEMOTHERAPY FOR COLORECTAL CANCER TREATMENT: CURRENT ADVANCES AND FUTURE PROSPECTS
Chemotherapy for colorectal cancer has made dramatic progress. With the use of various molecular-targeted agents and supportive therapies, a median survival of more than 30 months with improved quality of life (QOL) has been achieved even in patients with unresectable colorectal cancer. In order to select the appropriate therapy, genetic status, such as RAS/BRAF and HER2, is important, followed by the location of the primary tumor. The guidelines illustrate the process for primary treatment selection based on RAS/BRAF gene status and primary site. On the other hand, patients who are deemed resectable and undergo radical resection are treated with adjuvant chemotherapy to prevent recurrence. Currently, there is no way to stratify patients for adjuvant therapy other than by pathologic classification. New methods, such as circulating DNA (ctDNA: cancer-derived DNA released into the bloodstream), will be the focus of attention in the future.
To read the PDF file you will need Adobe Reader installed on your computer.